Financial Counselors Inc. Sells 954 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Financial Counselors Inc. lowered its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVAFree Report) by 1.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 57,083 shares of the company’s stock after selling 954 shares during the period. Financial Counselors Inc.’s holdings in Teva Pharmaceutical Industries were worth $805,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in TEVA. Lingotto Investment Management LLP lifted its position in shares of Teva Pharmaceutical Industries by 1.8% in the 4th quarter. Lingotto Investment Management LLP now owns 34,457,656 shares of the company’s stock worth $359,738,000 after purchasing an additional 607,800 shares during the period. Clal Insurance Enterprises Holdings Ltd lifted its position in Teva Pharmaceutical Industries by 7.1% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock valued at $342,788,000 after acquiring an additional 2,188,212 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its position in Teva Pharmaceutical Industries by 6.9% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock valued at $301,920,000 after acquiring an additional 1,860,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. lifted its position in Teva Pharmaceutical Industries by 3.0% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 28,533,099 shares of the company’s stock valued at $297,886,000 after acquiring an additional 821,759 shares during the period. Finally, AustralianSuper Pty Ltd lifted its position in Teva Pharmaceutical Industries by 18.8% during the 4th quarter. AustralianSuper Pty Ltd now owns 9,039,070 shares of the company’s stock valued at $94,368,000 after acquiring an additional 1,431,671 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a total value of $254,766.06. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Amir Weiss sold 15,500 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $16.80, for a total transaction of $260,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 17,814 shares in the company, valued at approximately $299,275.20. The disclosure for this sale can be found here. Insiders have sold 549,719 shares of company stock valued at $9,353,736 over the last 90 days. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $15.80 on Wednesday. The firm has a 50 day moving average of $16.41 and a 200 day moving average of $14.01. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.20. The firm has a market capitalization of $17.90 billion, a price-to-earnings ratio of -38.54, a price-to-earnings-growth ratio of 1.55 and a beta of 0.90. Teva Pharmaceutical Industries Limited has a 12-month low of $7.80 and a 12-month high of $17.69.

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.03). Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. The firm had revenue of $3.82 billion for the quarter, compared to analysts’ expectations of $3.70 billion. On average, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on TEVA shares. Piper Sandler reissued an “overweight” rating and set a $20.00 price target (up from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. Jefferies Financial Group raised their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Wednesday. Finally, Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, June 5th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.33.

Read Our Latest Analysis on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Profile

(Free Report)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Read More

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.